497863-61-3

Usage

Chemical Properties

Greenish Oil

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 22483-09-6 2,2-dimethoxyethylamine 

Downstream Products

• 497863-62-4 2-fluoro-3-isoquinolin-7-yl-but-2-enoic acid (2'-tert-butylsulfamoyl-biphenyl-4-yl)-amide 
• 497863-63-5 2-fluoro-3-isoquinolin-7-yl-but-2-enoic acid (2'-tert-butylsulfamoyl-3-chloro-biphenyl-4-yl)-amide 
• 288309-12-6 (2E) N-{4-[(2-tert-butylaminosulfonyl)phenyl]-2-fluorophenyl}-3-(isoquinolin-7-yl)-2-fluoro-3-methylacrylamide 
• 497863-64-6 2-fluoro-3-isoquinolin-7-yl-but-2-enoic acid (3-bromo-2'-tert-butylsulfamoyl-biphenyl-4-yl)-amide 
• 34784-04-8 5-bromoisoquinoline 
• 58794-09-5 7-bromoisoquinoline 

Relevant academic research and scientific papers

ANGIOGENESIS INHIBITORS

Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis:

Discovery of potent and practical antiangiogenic agents inspired by cortistatin A

The discovery that cortistatins A and J show noteworthy antiangiogenic activity prompted an investigation of the possibility that simpler and much more easily made compounds based on a steroid core might have useful bioactivity. These studies have led to

Substituted acrylamides as factor Xa inhibitors: Improving bioavailability by P1 modification

To overcome the low bioavailability of our substituted acrylamide P1 benzamidine factor Xa inhibitors reported previously, neutral and less basic groups were used to replace the benzamidine. As a result, a series of P1 aminoisoquinoline substituted acrylamide Xa inhibitors was identified to be potent, selective, and orally bioavailable. Modification of P4 moiety of these compounds further improved their pharmacokinetic properties.